Nuvectis Pharma Prices $100M Public Offering at $20.00, Below Market Price
NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (3.4× avg).
Summary
Nuvectis Pharma has priced its public offering of 5 million common shares at $20.00 per share, aiming to raise $100 million in gross proceeds. This significant capital raise, representing over 13% of the company's market cap, is priced at a discount to the current stock price of $23.12, implying substantial dilution for existing shareholders. The offering follows the company's recent Q1 2026 net loss of $6.05 million and $6.51 million cash burn, as well as the acquisition of exclusive rights to two new clinical-stage compounds, NXP100 and NXP200, which require funding. The offering is expected to close around July 1, 2026.
At the time of this announcement, NVCT was trading at $23.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $756.8M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.